DDX53 and neoplasm: Compared with DTT-FDwt treatment, DTT-FDmut treatment showed a better tumor inhibition effect in our CT26 preventive model (Figures 1C,D), which not only indicates that mutant KRAS G12D epitope is more important than any other non-mutant epitopes but also suggests that the CT26 model is efficient in detecting the Anti-Tumor activity of DTSP or DTT-SP4 containing the KRAS G12D mutant epitope.